Center for Wealth Management Advisory Sells 20,504 Shares of CVS Health Corporation $CVS

Center for Wealth Management Advisory trimmed its holdings in shares of CVS Health Corporation (NYSE:CVS) by 84.1% during the first quarter, Holdings Channel.com reports. The fund owned 3,879 shares of the pharmacy operator’s stock after selling 20,504 shares during the quarter. Center for Wealth Management Advisory’s holdings in CVS Health were worth $279,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. TOWER TRUST & INVESTMENT Co grew its position in shares of CVS Health by 0.8% during the 4th quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock worth $1,247,000 after purchasing an additional 132 shares in the last quarter. CYBER HORNET ETFs LLC increased its holdings in shares of CVS Health by 4.1% during the third quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock worth $259,000 after purchasing an additional 134 shares during the period. LS Investment Advisors LLC raised its position in shares of CVS Health by 3.9% in the fourth quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock valued at $284,000 after buying an additional 135 shares in the last quarter. Moss Adams Wealth Advisors LLC boosted its stake in shares of CVS Health by 4.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 3,016 shares of the pharmacy operator’s stock valued at $239,000 after buying an additional 135 shares during the period. Finally, Northwestern Mutual Investment Management Company LLC grew its holdings in shares of CVS Health by 0.3% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock worth $3,219,000 after purchasing an additional 136 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insider Transactions at CVS Health

In related news, Director Larry Robbins sold 1,983,538 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the transaction, the director directly owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. This represents a 24.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. The trade was a 87.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,441,551 shares of company stock worth $323,703,977 in the last three months. Insiders own 0.85% of the company’s stock.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Analysts highlighted CVS Health’s strong earnings surprise track record and said the company appears positioned to beat estimates again in its next quarterly report, which supports sentiment around future profits. Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: CVS was also featured in a CNBC report about Medicare beginning to cover obesity drugs, with CVS and Walmart helping seniors navigate the new coverage landscape, underscoring CVS’s role in a growing healthcare service area. Healthy Returns: Walmart, CVS step in to help seniors navigate Medicare coverage of obesity drugs
• Positive Sentiment: CVS Health also published consumer-health content on women’s health and preventive screenings, reinforcing its push to drive pharmacy, clinic, and health-services engagement. CVS Health: A Menopause Revolution Is Long Overdue
• Positive Sentiment: An executive from CVS Health was named to Choice Hotels’ board, which is a small signal of leadership visibility and management credibility. Choice Hotels International Appoints Artificial Intelligence Leader Ali Keshavarz to Board of Directors
• Neutral Sentiment: A healthcare-advice article said UnitedHealth, Humana, and CVS denied post-hospital care at some of the highest rates, which could keep attention on utilization management and prior-authorization practices, but the piece does not provide a direct financial update. UnitedHealth, Humana, CVS Denied Post-Hospital Care At Some Of The Highest Rates
• Neutral Sentiment: CVS also appeared in coverage of its support for America250, which is mainly a branding/community-relations item and likely has limited near-term stock impact. CVS Health Exec Explains Why Its Support of America250 is ‘Natural Fit’

CVS Health Stock Up 1.3%

Shares of CVS Health stock opened at $104.83 on Thursday. The stock’s 50-day moving average is $93.44 and its 200 day moving average is $82.96. CVS Health Corporation has a one year low of $58.50 and a one year high of $106.15. The firm has a market cap of $133.75 billion, a price-to-earnings ratio of 46.18, a PEG ratio of 1.01 and a beta of 0.60. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The business had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.During the same period in the previous year, the company posted $2.25 earnings per share. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts anticipate that CVS Health Corporation will post 7.44 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Leerink Partners reiterated an “outperform” rating and set a $98.00 price objective on shares of CVS Health in a research note on Thursday, March 5th. Barclays boosted their target price on shares of CVS Health from $101.00 to $106.00 and gave the company an “overweight” rating in a research report on Tuesday, May 26th. DA Davidson increased their price target on shares of CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Wall Street Zen lowered CVS Health from a “buy” rating to a “hold” rating in a research note on Monday. Finally, Morgan Stanley increased their price target on CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a research note on Thursday, June 4th. Twenty-one equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $101.28.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.